Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapirolizumab pegol - Biogen/UCB

Drug Profile

Dapirolizumab pegol - Biogen/UCB

Alternative Names: Anti-CD40L Fab; Anti-CD40L Fab-PEG; BIIB 133; CD40L - Fab; CDP-7657; DZP; Peg-dapirolizumab; Pegylated anti-CD40L antibody

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec; UCB
  • Developer ALS Therapy Development Institute; Biogen; UCB
  • Class Anti-inflammatories; Antibodies; Antirheumatics; Fab fragments; Polyethylene glycols
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • Phase II Multiple sclerosis
  • Discontinued Amyotrophic lateral sclerosis; Rheumatoid arthritis

Most Recent Events

  • 28 Jun 2024 Discontinued - Preclinical for Amyotrophic lateral sclerosis in USA (Parenteral)
  • 28 Jun 2024 Discontinued - Preclinical for Rheumatoid arthritis in United Kingdom (Parenteral)
  • 28 Nov 2022 Dapirolizumab pegol is still in the phase III PHOENYCS GO trial for Systemic lupus erythematosus (Adjunctive treatment, In adults, In adolescents, In the elderly) in the US, Argentina, Austria, Australia, Belgium, Bulgaria, Canada, Chile, Colombia, Czech Republic, France, Germany, Greece, Hong Kong, Hungary, Italy, South Korea, Mexico, Peru, Philippines, Poland, Portugal, Romania, Serbia, Spain, Taiwan, United Kingdom (IV) (NCT04294667) (EudraCT2019-003406-27)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top